$RLFTF DD by Sparks (copy) : Sharing a summary of the

New Post Public Reply Private Reply Replies (0) Message Board
mc67
541
$RLFTF DD by Sparks (copy) : Sharing a summary of the interview with Dr. Javitt I put together for myself because of the confusion this week with PRs etc. Dr. Javitt appeared to be confident and very encouraging.

Regarding primary endpoint: The primary endpoint is recovery from respiratory failure - meaning patients get better and go home - it is NOT mortality. This was discussed with the FDA early on in the study, along with a timeline of 60 days based on what they saw with Dr. Youssef's open label study at Houston Methodist last fall. The 28 day timeline was included originally because that has been the historical standard since the 90's for ARDS studies but it isn't really relevant anymore. The FDA told them that ultimately they care about how patients feel, function and survive.

Regarding the timeline: the last patient was enrolled on Dec 24 and Day 60 for that patient will be February 20th. At Houston Methodist, they achieved statistical significance and a larger difference between days 28 and 60.

Regarding the release of topline data to the public: they are tracking and cleaning it in real-time and not waiting for the last patient but it can still take a week or two after the last patient is finished to look at the entire dataset and clean up discrepancies etc.

Regarding the EUA: they don't have to submit a new application and they are building off of the previous application from last fall by adding important new data from this study. The FDA told them they wanted randomized control data to make a decision about the EUA and so they are providing that now. The drug did not have a meaningful safety database previously either until now, and so they can now say with confidence that it is safe.

Regarding additional information: For additional supportive information they are having radiologists review x-rays in a blinded manner to see if they are consistent with the open label results.

Regarding the PRs: They released the PR this week because it is material information that investors should be aware of and it is significant because there is a precedent with Remdesivir as it was approved for EUA based on a statistically significant reduction in hospital days and Zyesami shows this as well in a more significant way.

Regarding the significance of secondary endpoints like reduced hospital days, reduced ICU days and improved NIAID scores : They are showing statistical significance across the board. There are obviously the financial and logistical benefits to having people go home earlier, but more importantly for the study it shows that something biological happened to get them better and home sooner. they now need to look at the data further to calculate the time to resolution for respiratory failure.

Regarding manufacturing: they have teamed with Nephron Pharma for the inhaled sterile products and are feeling good about that, they have built a supply chain and can supply as much raw material (aviptadil is the raw material) as needed in North America and Israel now and within a few months will have enough for the rest of the world.

Regarding marketing: Robert Besthof is handling building up a commercially capable company. Some large partnerships will be announced in the near future regarding this. He did say that Cardinal Health is the logistics partner that can get the drug anywhere overnight.

He isn't too worried about marketing - if the FDA grants the EUA people will know about it and Drs will want it - the drug speaks for itself. Regardless they have a team, a plan in place and some partnerships they will be announcing.

He talked about a bunch of other stuff like requirements for NDA (new drug approval) versus EUA, the inhaled trial they have started with UC Irvine and will announce additional study sites in the next few weeks, how Zyesami is included in the I-SPY trial supported by Barda that will compare multiple promising new drugs against each other (this will be the inhaled version), they are actively looking into chronic covid longhaulers and how this can help with acute lung injury. He said that even if covid disappears in a year ARDS continues to be a problem and the previous studies for this didn't advance mainly due to no commercial supply or long term formulation available. He said that Zyesami should work with the new variants because of what it targets as opposed to vaccines that target a specific protein. They are working on standing up a research program in the next couple of months to measure this.

A great call and put my mind at ease - I hope this helps you if you don't have time to watch the video.

Mondobiotech Holding AG Basel (RLFTF) Stock Research Links

RLFTF Board Company Profile Buy Rating Time & Sales News Filings Financials
$MJ
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 136

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 92

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 155

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 178

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 205

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 121

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 76

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 239

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 95

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Vivid Seats Simplifies Market Structure and Tax Obligations

Updated Category News Views 221

Vivid Seats Streamlines Corporate Structure Vivid Seats Inc. (NASDAQ: SEAT), a leading online ticket marketplace, has embarked on a transformative journey to simplify its organizational framework. In a strategic move, the company has announced its Corporate Simplification Agreement, aimed at redefining how it operates while enhancing its tax efficiency and overall...

Continue Reading
NLS Pharmaceuticals Soars After Major Merger Announcement

Updated Category News Views 330

NLS Pharmaceuticals Sees Positive Stock Movement NLS Pharmaceuticals Ltd. (NASDAQ: NLSP) is experiencing significant upward momentum in its stock prices following a crucial announcement regarding a proposed merger. The company has filed a Form F-4 registration statement with the Securities and Exchange Commission, signaling an essential step toward completing this merger....

Continue Reading
Orchestra BioMed Achieves Key Financial and Operational Progress

Updated Category News Views 84

Orchestra BioMed Reports on Financial Performance and Business Updates Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO), a pioneering biomedical innovation company, recently presented its robust financial results for Q3 2024, reflecting both significant fiscal health and promising advancements in medical technology. The company is focused on elevating patient care through...

Continue Reading
Nutex Health Inc. Investors Urged to Join Securities Class Action

Updated Category News Views 130

Investors of Nutex Health Inc. Face Opportunities Amid Allegations Investors holding shares in Nutex Health Inc. are currently presented with a remarkable opportunity in light of claims surrounding securities fraud involving the Company. Founded as a notable player in the healthcare sector, Nutex Health has recently come under scrutiny due to alleged misleading statements...

Continue Reading
Empowering Resilience in Education: Embracing Failure with LetMeFail

Updated Category News Views 182

Transforming Education: LetMeFail's Innovative Approach LetMeFail is an exciting new educational initiative aimed at transforming how students perceive and deal with failure. In today's culture, where perfection is often idolized, this program makes it clear that setbacks can serve as important stepping stones toward personal growth and resilience. Unpacking the Goals of...

Continue Reading